Hologenix has organized seven completed clinical studies to date, with two more underway. Initially the focus was to prove that Celliant increased blood oxygen levels by measuring transcutaneous oxygen levels (TCPO2), a practice commonly used for people suffering from hypoxia, peripheral vascular disease or any other condition that inhibits blood flow. Dr. Lawrence Lavery and Dr. Graham McClue commissioned two studies in 2003 and 2005 respectively. Both tests measured oxygen levels first among subjects with previous vascular conditions then among healthy subjects. In 2008, Hologenix commissioned a dual study with Dr. Ian Gordon measuring TCPO2 levels in healthy subjects and also a study designed to measure Celliant's effect on pain levels in subjects suffering from chronic foot pain. In 2009, a pilot study began measuring the effects of Celliant on subjects with significant sleep trouble. The study was renewed in 2010 and when results are available they will be posted here.